Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Bone Marrow Transplant ; 49(1): 95-101, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24121212

RESUMO

This study was aimed at finding predictors of invasive fungal infection (IFI) after pediatric allogeneic hematopoietic SCT (HSCT). All children who received allogeneic HSCT in the Wilhelmina Children's Hospital Utrecht between 2004 and 2012 were included. HSCT data were prospectively collected. Patients were retrospectively classified into high- or low-risk groups for developing IFI using criteria based on available literature. Predictors for the occurrence of IFI were analyzed using Cox regression models. We used logistic regression models to analyze the association between other HSCT-related complications and IFI. Secondary outcomes were overall survival and treatment-related mortality (TRM). Two-hundred nine patients were included in the analysis; median age was 6.6 years. The cumulative incidence of IFI was 12%. In patients classified as 'low risk' (n=75), only 5.3% developed IFI (odds ratio (OR): 0.325; P=0.047). In multivariate analysis, a predictor for the occurrence of IFI was an a priori determined HSCT TRM risk >20% (based on EBMT-risk score). Post-HSCT, the administration of high-dose steroids was associated with IFI (OR: 4.458; P=0.010). Patients who developed IFI showed an increased risk of TRM (OR: 3.773; P=0.004). These results confirm that risk group stratification should guide intensity of monitoring for IFI and use of antifungal prophylaxis.


Assuntos
Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Micoses/complicações , Micoses/diagnóstico , Adolescente , Adulto , Anfotericina B/uso terapêutico , Antifúngicos/uso terapêutico , Aspergilose/complicações , Candidíase/complicações , Caspofungina , Criança , Pré-Escolar , Equinocandinas/uso terapêutico , Feminino , Fusariose/complicações , Doença Enxerto-Hospedeiro/tratamento farmacológico , Humanos , Lactente , Lipopeptídeos , Modelos Logísticos , Masculino , Neutrófilos/citologia , Estudos Prospectivos , Pirimidinas/uso terapêutico , Estudos Retrospectivos , Risco , Resultado do Tratamento , Triazóis/uso terapêutico , Voriconazol , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...